Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00574080 · ClinicalTrials.gov registry record · Phase 3
UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide
A Phase 3 study, sponsored by University of Arkansas.
- Terminated
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
NCT00574080: Clinical Trial Phase 3 study, sponsored by University of Arkansas.
NCT00574080 is a Phase 3 study that was terminated before completion, run by University of Arkansas. The registered enrollment target is 20 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00574080, a Phase 3 study, was terminated before completion, sponsored by University of Arkansas.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
Study Summary
Add three drugs, bortezomib, thalidomide, and dexamethasone (VTD) to the high dose chemotherapy regimen immediately before transplant (DPACE/Melphalan) to try to improve myeloma response and acquire longer survival for participants.
Primary Outcome
Time from study registration until disease progression or death.
Interventions
- DRUG Interim/Maintenance Dexamethasone
- DRUG Induction/Consolidation Dexamethasone
- DRUG Induction/Consolidation Cisplatin
- DRUG Induction/Consolidation Adriamycin
- DRUG InductionConsolidation Cyclophosphamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-07 |
| Est. Completion | 2011-03 |
| Phase | Phase 3 |
Why NCT00574080 stopped before completion
NCT00574080 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 5 interventions - of which Interim/Maintenance Dexamethasone is the first listed.
NCT00574080 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00574080 about?
NCT00574080 is a clinical study titled "UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide". Add three drugs, bortezomib, thalidomide, and dexamethasone (VTD) to the high dose chemotherapy regimen immediately before transplant (DPACE/Melphalan) to try to improve myeloma response and acquire longer survival for participants.
What is the current status of trial NCT00574080?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2006-07. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00574080?
The interventions under investigation include: Interim/Maintenance Dexamethasone (DRUG), Induction/Consolidation Dexamethasone (DRUG), Induction/Consolidation Cisplatin (DRUG), Induction/Consolidation Adriamycin (DRUG), InductionConsolidation Cyclophosphamide (DRUG).
Who is sponsoring clinical trial NCT00574080?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00574080's enrollment target sits among peer trials
20 1956th of 2000 higher than 32 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia